Latest & greatest articles for lorazepam

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lorazepam or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lorazepam and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lorazepam

1. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. (Full text)

Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. The use of benzodiazepines to control agitation in delirium in the last days of life is controversial.To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer.Single-center, double-blind, parallel-group, randomized clinical (...) trial conducted at an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled haloperidol from February 11, 2014, to June 30, 2016, with data collection completed in October 2016.Lorazepam (3 mg) intravenously (n = 47) or placebo (n = 43) in addition to haloperidol (2 mg) intravenously upon the onset of an agitation episode.The primary outcome was change in Richmond Agitation-Sedation Scale (RASS) score (range

2017 JAMA PubMed

2. A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus

A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus Cock H R, Schapira A H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Lorazepam was compared with diazepam as first-line treatment for convulsive status epilepticus (CSE). The dose of lorazepam was 4 mg intravenously (i.v.), repeated up to 2 times. The dose of diazepam was 10 mg i.v., repeated up to 3 times. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged over

2002 NHS Economic Evaluation Database.

3. A Comparative Study of the Clinical Efficacy and Safety of Lorazepam and Chlordiazepoxide in Alcohol Dependence Syndrome (Full text)

A Comparative Study of the Clinical Efficacy and Safety of Lorazepam and Chlordiazepoxide in Alcohol Dependence Syndrome Currently, benzodiazepines are the preferred drugs in the management of alcohol withdrawal symptoms. Chlordiazepoxide and diazepam, the most frequently used drugs have a long duration of action and are converted to active metabolites in the liver, while lorazepam is shorter acting, with no active metabolites.To compare and evaluate the safety and efficacy of lorazepam (...) and chlordiazepoxide in patients with alcohol dependence syndrome with symptoms of alcohol withdrawal.This was a prospective, randomized, double-blind, study carried out at a teaching hospital in Bangalore. Sixty patients aged ≥18 y with alcohol dependence syndrome with mild-to-moderate withdrawal symptoms were allocated at a ratio of 1:1 to either lorazepam or chlordiazepoxide, by means of a computer-generated randomization chart. Thirty patients each were started with lorazepam tablets 8 mg/day

2015 Journal of clinical and diagnostic research : JCDR PubMed

4. Lorazepam confirmed as first-line treatment for stopping prolonged seizures in children

Lorazepam confirmed as first-line treatment for stopping prolonged seizures in children Lorazepam confirmed as first-line treatment for stopping prolonged seizures in children Discover Portal Discover Portal Lorazepam confirmed as first-line treatment for stopping prolonged seizures in children Published on 17 April 2018 doi: Intravenous lorazepam is as effective as intravenous diazepam for stopping children’s tonic-clonic seizures in hospital. Lorazepam also results in fewer breathing problems (...) comparing buccal midazolam with rectal diazepam were graded as low to very low evidence, and because of the uncertainty, the authors considered that the new evidence did not support the use of buccal midazolam when intravenous access was difficult. What did it find? Intravenous lorazepam appears to be as effective as intravenous diazepam in stopping acute tonic-clonic seizures, (risk ratio [RR] 1.04, 95% confidence interval [CI] 0.94 to 1.16; three trials, 414 children). Compared to other routes

2019 NIHR Dissemination Centre

5. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial (Full text)

Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial Pandharipande PP, Pun BT, Herr DL (...) of dexmedetomidine for sedation of adult medical and surgical intensive care unit patients who required mechanical ventilation for more than 24 hours. The authors concluded that compared with lorazepam, dexmedetomidine reduced duration of delirium and coma and increased time at the targeted level of sedation at no added cost. Reporting and methodology were satisfactory. The authors' conclusions appear appropriate but readers should take into account the limited generalisability and lack of uncertainty assessment

2007 NHS Economic Evaluation Database. PubMed

6. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. (Full text)

Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. Benzodiazepines are considered first-line therapy for pediatric status epilepticus. Some studies suggest that lorazepam may be more effective or safer than diazepam, but lorazepam is not Food and Drug Administration approved for this indication.To test the hypothesis that lorazepam has better efficacy and safety than diazepam for treating pediatric status epilepticus.This double-blind, randomized clinical trial (...) was conducted from March 1, 2008, to March 14, 2012. Patients aged 3 months to younger than 18 years with convulsive status epilepticus presenting to 1 of 11 US academic pediatric emergency departments were eligible. There were 273 patients; 140 randomized to diazepam and 133 to lorazepam.Patients received either 0.2 mg/kg of diazepam or 0.1 mg/kg of lorazepam intravenously, with half this dose repeated at 5 minutes if necessary. If status epilepticus continued at 12 minutes, fosphenytoin

2014 JAMA PubMed

7. Intranasal Lorazepam Is an Acceptable Alternative To Intravenous Lorazepam In The Control Of Acute Seizures In Children

Intranasal Lorazepam Is an Acceptable Alternative To Intravenous Lorazepam In The Control Of Acute Seizures In Children BestBets: Intranasal Lorazepam Is an Acceptable Alternative To Intravenous Lorazepam In The Control Of Acute Seizures In Children Intranasal Lorazepam Is an Acceptable Alternative To Intravenous Lorazepam In The Control Of Acute Seizures In Children Report By: Anna Allan, Jayne Cullen - Final Year Medical Students Search checked by Dr Adrian Boyle - Emergency Department (...) Consultant Institution: University of Cambridge School of Clinical Medicine, Cambridge, UK Date Submitted: 2nd December 2011 Date Completed: 30th August 2013 Last Modified: 30th August 2013 Status: Green (complete) Three Part Question In [children presenting to the ED with seizures] is [intranasal Lorazepam an acceptable intervention] for achieving [termination of seizures]? Clinical Scenario A 4 year old child is brought to the Emergency Department by her parents. She presents with protracted seizures

2013 BestBETS

8. Lorazepam

Lorazepam Top results for lorazepam - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lorazepam The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

9. Effect of adjuvant sleep hygiene psychoeducation and lorazepam on depression and sleep quality in patients with major depressive disorders: results from a randomized three-arm intervention. (Full text)

Effect of adjuvant sleep hygiene psychoeducation and lorazepam on depression and sleep quality in patients with major depressive disorders: results from a randomized three-arm intervention. Sleep disturbances are a common co-occurring disturbance in patients with major depressive disorders (MDDs) and accordingly deserve particular attention. Using a randomized design, we investigated the effects of three different adjuvant interventions on sleep and depression among patients with MDD: a sleep (...) hygiene program (SHP), lorazepam (LOR), and their combination (SHP-LOR).A total of 120 outpatients with diagnosed MDD (mean age: 48.25 years; 56.7% females) and treated with a standard SSRI (citalopram at 20-40 mg at therapeutic level) were randomly assigned to one of the following three conditions: SHP (n=40), LOR (1 mg/d; n=40), SHP-LOR (1 mg/d; n=40). At the beginning and at the end of the study 8 weeks later, patients completed two questionnaires, the Pittsburgh Sleep Quality Index to assess sleep

2016 Neuropsychiatric disease and treatment PubMed

10. A Comparative Study of Fixed Tapering Dose Regimen versus Symptom-triggered Regimen of Lorazepam for Alcohol Detoxification. (Full text)

A Comparative Study of Fixed Tapering Dose Regimen versus Symptom-triggered Regimen of Lorazepam for Alcohol Detoxification. The study aimed at comparing the fixed tapering dose and the symptom-triggered regimens of lorazepam for alcohol detoxification.We carried out a prospective, randomized, double blind controlled trial involving 63 consecutive consenting male patients admitted with diagnosis of uncomplicated alcohol withdrawal. The patients were randomized into two groups based on the type (...) of lorazepam dosage: symptom-triggered (n = 33) and fixed tapering dose regimens (n = 30). Alcohol withdrawal symptoms were rated on CIWA-Ar (Clinical Institute Withdrawal Assessment - Alcohol revised). The main outcome measures were the total amount and duration of lorazepam treatment and the incidence of adverse events or complications.The mean lorazepam dose administered in the symptom-triggered group was significantly lower than in the fixed tapering dose group (9.5 versus 19.9 mg, P < 0.001

2014 Alcohol and alcoholism (Oxford, Oxfordshire) PubMed

11. Intravenous Lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: a randomized clinical trial. (PubMed)

Intravenous Lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: a randomized clinical trial. To determine whether lorazepam is more effective than dimenhydrinate in relieving the symptom of vertigo in the emergency department setting.A prospective, randomized, double-blind trial of intravenous lorazepam versus dimenhydrinate therapy was conducted in the ED of a county-owned, university-affiliated hospital. All adult patients who presented between January 24 (...) , 1998, and May 23, 1999, with the symptom of vertigo were eligible for inclusion. The intervention was varying the intravenous treatment between lorazepam, 2 mg, and dimenhydrinate, 50 mg. All patients received intravenous infusion of Ringer's lactate solution at a rate of 100 mL/h. Adequacy of randomization to the 2 treatment groups was assessed by comparing the patients' relevant baseline history, physical examination, and symptoms. The predetermined primary outcome measurement was the patient's

2000 Annals of Emergency Medicine

12. Intravenous diazepam, midazolam and lorazepam in acute seizure control. (PubMed)

Intravenous diazepam, midazolam and lorazepam in acute seizure control. To evaluate the safety and efficacy of three benzodiazepine drugs: Lorazepam, Midazolam and Diazepam, when given parenterally in the control of acute seizure.One hundred and twenty children of either sex in the age group 6 month to 14 years brought convulsing to the pediatric emergency services, were enrolled in the study. These were randomised to three equal groups of 40 patients each; Group A-received diazepam, Group B (...) -received midazolam, Group C-received lorazepam. End of seizure episode (clinically) was defined as cessation of visible epileptic phenomenon or return of purposeful response to external stimuli within 15 min of drug administration. A stopwatch was used to measure various time intervals accurately. The patient's vitals were monitored and recorded in a predesigned performa. The primary outcome was the time to seizure cessation and secondary outcome was the side effects of the drugs. Data obtained

2012 Indian journal of pediatrics

13. Randomised controlled trial: Pregabalin similar to lorazepam for alcohol withdrawal symptoms

Randomised controlled trial: Pregabalin similar to lorazepam for alcohol withdrawal symptoms Pregabalin similar to lorazepam for alcohol withdrawal symptoms | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregabalin similar to lorazepam for alcohol withdrawal symptoms Article Text Therapeutics Randomised controlled trial Pregabalin similar to lorazepam for alcohol withdrawal symptoms Giovanni Addolorato 1 , Lorenzo Leggio 1 , 2

2010 Evidence-Based Medicine (Requires free registration)

14. Review: lorazepam provides the best control for status epilepticus (Full text)

Review: lorazepam provides the best control for status epilepticus Review: lorazepam provides the best control for status epilepticus | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: lorazepam provides the best control for status epilepticus Article Text Therapeutics Review: lorazepam provides the best control for status epilepticus Free J Craig Henry , MD , Robert Holloway , MD, MPH Statistics from Altmetric.com Prasad K, Al

2007 Evidence-Based Medicine (Requires free registration) PubMed

15. Lorazepam

Lorazepam Lorazepam Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Lorazepam Lorazepam Aka: Lorazepam , Ativan From Related Chapters (...) II. Indications Preanesthetic medication III. See Also IV. Class Medium Acting V. Pharmacokinetics Half Life: 10-20 hours VI. Dosing Dose: 0.5 to 2 mg IV, IM or PO every 6 to 8 hours Maximum Daily Dose: 4 mg VII. Dosing: Equivalent (for Benzodiazepine Withdrawal) = Dose x5.0 Phenobarbital = Dose x15.0 Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Lorazepam." Click on the image (or right click) to open the source website

2018 FP Notebook

16. Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam - Pilot study. (PubMed)

Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam - Pilot study. This study was conducted to compare the efficacy of phenytoin, valproate and levetiracetam in patients with GCSE.This randomised controlled prospective study was conducted on 150 patients to compare the efficacy of phenytoin (n = 50), valproate (n = 50) and levetiracetam (n (...) = 50) along with lorazepam in patients with GCSE. All recruited patients received i.v. lorazepam (0.1mg/kg) followed by one of the 3 AEDs viz. phenytoin (20 mg/kg), valproate (30 mg/kg), and levetiracetam (25 mg/kg). Those who remained uncontrolled with 1st AED, received the other two AEDs sequentially. Clinical, imaging, EEG, etiological factors were analysed. Predictors of poor seizure control and outcome at discharge and at one month follow-up were assessed.In the phenytoin subgroup

2015 Epilepsy research

17. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. (PubMed)

A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Generalized and persistent anxiety, accompanied by nervousness and other symptoms (Generalised Anxiety Disorder, GAD) is frequent in the general population and leads to benzodiazepine usage. Unfortunately, these substances induce sedation and have a high potential for drug abuse, and there is thus a need for alternatives. As the anxiolytic (...) properties of lavender have already been demonstrated in pharmacological studies and small-scale clinical trials, it was postulated that lavender has a positive effect in GAD. A controlled clinical study was then performed to evaluate the efficacy of silexan, a new oral lavender oil capsule preparation, versus a benzodiazepine. In this study, the efficacy of a 6-week-intake of silexan compared to lorazepam was investigated in adults with GAD. The primary target variable was the change in the Hamilton

2010 Phytomedicine : international journal of phytotherapy and phytopharmacology

18. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. (Full text)

Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. To compare the efficacy and safety profile between intramuscular (IM) olanzapine and IM haloperidol plus IM lorazepam in acute schizophrenic patients with moderate to severe agitation.This was a prospective, randomized, open-label study. Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were (...) randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30). Agitation was measured with Positive and Negative Syndrome Scale Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES) during the first 2 hours and at 24 hours after the first injection. Safety was assessed using the Simpson-Angus Scale and Barnes Akathisia Rating Scale and by recording adverse events at 24 hours following the first injection. The Clinical Global Impression

2015 Journal of the Formosan Medical Association = Taiwan yi zhi PubMed

19. A double blind randomised comparison of chlordiazepoxide and lorazepam in alcohol withdrawal.

A double blind randomised comparison of chlordiazepoxide and lorazepam in alcohol withdrawal. To compare the efficacy of lorazepam and chlordiazepoxide in alcohol withdrawal in a double blind design.The study sample consisted of 108 consecutive admissions to the de addiction ward, which after informed consent and selection based on inclusion criteria, were randomised to two groups. A comparison of the efficacy of chlordiazepoxide and lorazepam was done post randomisation. The initial withdrawal (...) assessment and subsequent progress of withdrawal were assessed using Clinical Institute Assessment for Alcohol-revised (CIWA-Ar). The rate of withdrawal and total duration of withdrawal were compared among the two groups.Lorazepam treated group showed a significant difference in the rate of improvement over 48 h compared to chlordiazepoxide group (70.4% vs. 54.8%; p=0.000). The total duration of withdrawal was also significantly lesser with lorazepam (5.6 days vs. 6.7 days; p=0.001).Lorazepam is more

2013 Asian journal of psychiatry

20. Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials. (PubMed)

Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials. Some guidelines or expert consensus indicate that intravenous (IV) lorazepam (LZP) is preferable to IV diazepam (DZP) for initial treatment of convulsive status epilepticus (SE). We aimed to critically assess all the available data on efficacy and tolerability of IV LZP compared

2016 Epilepsy & behavior : E&B